Evidence map›Paper›PMID 27606422›Full record

ArticlePloS one2016

Developmental Neurotoxic Effects of Percutaneous Drug Delivery: Behavior and Neurochemical Studies in C57BL/6 Mice.

Huali Wu, Junyi Feng, Wenting Lv, Qiaoling Huang, Mengsi Fu, Minxuan Cai, Qiangqiang He, Jing Shang

Abstract read
In one paragraph

Article in PloS one, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Isotretinoin-associated vivid dreams during acne therapy.International journal of dermatology · 2024
    Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Psychiatric and Developmental Effects of Isotretinoin (Retinoid) Treatment for Acne Vulgaris.Current therapeutic research, clinical and experimental · 2019
    Review
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Huali WuState Key Laboratory of Natural Medicines, China Pharmaceutical University, Nanjing, China.
Junyi FengState Key Laboratory of Natural Medicines, China Pharmaceutical University, Nanjing, China.
Wenting LvState Key Laboratory of Natural Medicines, China Pharmaceutical University, Nanjing, China.
Qiaoling HuangState Key Laboratory of Natural Medicines, China Pharmaceutical University, Nanjing, China.
Mengsi FuState Key Laboratory of Natural Medicines, China Pharmaceutical University, Nanjing, China.
Minxuan CaiState Key Laboratory of Natural Medicines, China Pharmaceutical University, Nanjing, China.
Qiangqiang HeQinghai Key Laboratory of Tibetan Medicine Pharmacology and Safety Evaluation, Northwest Institute of Plateau Biology, Chinese Academy of Sciences, Xining, QingHai Province, PR China.
Jing ShangState Key Laboratory of Natural Medicines, China Pharmaceutical University, Nanjing, China.ORCID http://orcid.org/0000-0003-4891-7742

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Dermatosis often as a chronic disease requires effective long-term treatment; a comprehensive evaluation of mental health of dermatology drug does not receive enough attention. An interaction between dermatology and psychiatry has been increasingly described. Substantial evidence has accumulated that psychological stress can be associated with pigmentation, endocrine and immune systems in skin to create the optimal responses against pathogens and other physicochemical stressors to maintain or restore internal homeostasis. Additionally, given the common ectodermal origin shared by the brain and skin, we are interested in assessing how disruption of skin systems (pigmentary, endocrine and immune systems) may play a key role in brain functions. Thus, we selected three drugs (hydroquinone, isotretinoin, tacrolimus) with percutaneous excessive delivery to respectively intervene in these systems and then evaluate the potential neurotoxic effects. Firstly, C57BL/6 mice were administrated a dermal dose of hydroquinone cream, isotretinoin gel or tacrolimus ointment (2%, 0.05%, 0.1%, respectively, 5 times of the clinical dose). Behavioral testing was performed and levels of proteins were measured in the hippocampus. It was found that mice treated with isotretinoin or tacrolimus, presented a lower activity in open-field test and obvious depressive-like behavior in tail suspension test. Besides, they damaged cytoarchitecture, reduced the level of 5-HT-5-HT1A/1B system and increased the expression of apoptosis-related proteins in the hippocampus. To enable sensitive monitoring the dose-response characteristics of the consecutive neurobehavioral disorders, mice received gradient concentrations of hydroquinone (2%, 4%, 6%). Subsequently, hydroquinone induced behavioral disorders and hippocampal dysfunction in a dose-dependent response. When doses were high as 6% which was 3 times higher than 2% dose, then 100% of mice exhibited depressive-like behavior. Certainly, 6% hydroquinone exposure elicited the most serious impairment of hippocampal structure and survival. The fact that higher doses of hydroquinone are associated with a greater risk of depression is further indication that hydroquinone is responsible for the development of depression. These above data demonstrated that chronic administration of different dermatology drugs contributed into common mental distress. This surprising discovery of chemical stressors stimulating the hippocampal dysfunction, paves the way for exciting areas of study on the cross-talk between the skin and the brain, as well as is suggesting how to develop effective and safe usage of dermatological drugs in daily practice.

Indexed as

Behavior, AnimalDrug Delivery SystemsNeurochemistryAdministration, TopicalAnimalsApoptosisCell SurvivalHippocampusHydroquinonesIsotretinoinMaleMice, Inbred C57BLModels, BiologicalNeurotoxicity SyndromesReceptor, Serotonin, 5-HT1AReceptor, Serotonin, 5-HT1BhydroquinoneHydroquinonesIsotretinoinReceptor, Serotonin, 5-HT1AReceptor, Serotonin, 5-HT1BSerotoninTacrolimus

Identifiers

PMID27606422
PMCPMC5015905

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.